Evidence map›Paper›PMID 33574755›Full record

ArticleFrontiers in pharmacology2020

Linjie Ju, Peipei Hu, Ping Chen, Jiejie Wu, Zhuoqun Li, Zhixia Qiu, Jun Cheng, Fang Huang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Linjie JuDepartment of Chinese Pharmacology and Traditional Chinese Medicine, China Pharmaceutical University, Nanjing, China.
Peipei HuDepartment of Chinese Pharmacology and Traditional Chinese Medicine, China Pharmaceutical University, Nanjing, China.
Ping ChenDepartment of Chinese Pharmacology and Traditional Chinese Medicine, China Pharmaceutical University, Nanjing, China.
Jiejie WuDepartment of Chinese Pharmacology and Traditional Chinese Medicine, China Pharmaceutical University, Nanjing, China.
Zhuoqun LiDepartment of Chinese Pharmacology and Traditional Chinese Medicine, China Pharmaceutical University, Nanjing, China.
Zhixia QiuDepartment of Chinese Pharmacology and Traditional Chinese Medicine, China Pharmaceutical University, Nanjing, China.
Jun ChengNanjing Zhongshan Pharmaceutical Co, Ltd., Nanjing Economic and Technological Development Zone, Nanjing, China.
Fang HuangDepartment of Chinese Pharmacology and Traditional Chinese Medicine, China Pharmaceutical University, Nanjing, China.
China Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastatic bone pain is characterized by insufferable bone pain and abnormal bone structure. A major goal of bone cancer treatment is to ameliorate osteolytic lesion induced by tumor cells.

Indexed as

cancer induced bone painCorydalis saxicola bunting total alkaloidsIκBαosteoclastogenesisRANKL induced NF-κB and c-fos/NFATc1 pathways

Identifiers

PMID33574755
PMCPMC7870471
OpenAlexW3122557521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.